Inhibitor Therapeutics, Inc.
INTI
$0.05
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.84% | -15.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.52% | 3.14% | |||
| Operating Income | -6.52% | -3.14% | |||
| Income Before Tax | -7.93% | -4.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.93% | -4.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.93% | -4.28% | |||
| EBIT | -6.52% | -3.14% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -7.89% | -2.70% | |||
| Normalized Basic EPS | -8.33% | -4.35% | |||
| EPS Diluted | -7.89% | -2.70% | |||
| Normalized Diluted EPS | -8.33% | -4.35% | |||
| Average Basic Shares Outstanding | 0.00% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||